Czechia· CZ-0219117
PARSABIV
A etelcalcetide product containing etelcalcetide hydrochloride, registered in Czechia by Amgen Europe B.V., Breda. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Etelcalcetide is registered in 14 of 19 countries.
Countries holding a registration under ATC H05BX04 (etelcalcetide), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 10 of them publish a price we can compare per daily dose
Etelcalcetide · ATC H05BX04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ETELCALCETIDE HYDROCHLORIDE
- Manufacturer
- Amgen Europe B.V., Breda
- Country
- Czechia (CZ)
- ATC code
- H05BX04
- ATC class
- Etelcalcetide
- Defined daily dose
- 2.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02191176X0,5MLCZK 2872.34
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for etelcalcetide.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etelcalcetide · interactions on record
20 records
- 19 severe
- 1 moderate
Most severe, free to view
- FurosemideC03CA01severe
- BumetanideC03CA02severe
- TorasemideC03CA04severe
- Etacrynic acidC03CC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etelcalcetide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumParsabiv 2.5 mgAmgen Europe
- SpainPARSABIV 2,5 MG SOLUCION INYECTABLEAmgen Europe B.V.
- IcelandParsabivAmgen Europe B.V.*
- PolandParsabivAmgen Europe B.V.
- SwedenParsabiv 2,5 mg Injektionsvätska, lösningAmgen Europe B.V.
- SwitzerlandParsabiv 10.0 mg, InjektionslösungAmgen Switzerland AG
- FinlandParsabivAmgen Europe B.V.
- FrancePARSABIV 10 mg, solution injectableAMGEN EUROPE
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Parsabiv
- Norway · Parsabiv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7831f311-df56-4a9c-b31b-4ebf05d89bed GET /v1/drugs/7831f311-df56-4a9c-b31b-4ebf05d89bed?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL",
"source": "sukl",
"strength": "2,5MG",
"pack_size": "6X0,5ML",
"substance": "ETELCALCETIDE HYDROCHLORIDE",
"cz_kod_sukl": "0219117",
"product_type": null,
"substance_codes": "21241",
"registration_state": "R",
"registration_number": "EU/1/16/1142/002"
}See everything about etelcalcetide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.